First description of rpsJ and mepA mutations associated with tigecycline resistance in Staphylococcus aureus isolated from a cystic fibrosis patient during antibiotic therapy

Sader, 2016, Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011–2014), Int J Antimicrob Agents, 48, 144, 10.1016/j.ijantimicag.2016.04.021

Garza-Gonzalez, 2013, Changes in Staphylococcus aureus susceptibility across Latin America between 2004 and 2010, Braz J Infect Dis, 17, 13, 10.1016/j.bjid.2012.08.017

Herrera, 2016, In vitro selection of Staphylococcus aureus mutants resistant to tigecycline with intermediate susceptibility to vancomycin, Ann Clin Microbiol Antimicrob, 15, 15, 10.1186/s12941-016-0131-7

Beabout, 2015, The ribosomal S10 protein is a general target for decreased tigecycline susceptibility, Antimicrob Agents Chemother, 59, 5561, 10.1128/AAC.00547-15

McAleese, 2005, A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline, Antimicrob Agents Chemother, 49, 1865, 10.1128/AAC.49.5.1865-1871.2005